Bunazosin

Bunazosin

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	none
Identifiers
IUPAC name 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one
CAS Number	80755-51-7
PubChem CID	2472
ChemSpider	2378 Y
UNII	9UUW4V7G2H
ChEMBL	ChEMBL188185 Y
CompTox Dashboard (EPA)	DTXSID7022700
Chemical and physical data
Formula	C19H27N5O3
Molar mass	373.457 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
InChI InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22) Y Key:RHLJLALHBZGAFM-UHFFFAOYSA-N Y
(verify)

Bunazosin (INN) is an α₁-adrenergic receptor antagonist.^[1] Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e